Australia New Zealand
Therapeutic Products
Authority

Information last updated: 27 July 2006
URL: http://www.anztpa.org/cm/
   0607pres-is-hae.htm

• Home
• About the project
• Contact us
• Media centre
• A-Z guide
• Glossary
• Consultations
• Questions & answers
• Fact sheets
• ANZTPA Orders

• Advertising scheme
• Manufacturing
• Medicines labelling
• Prescription medicines
• Complementary medicines
• OTC medicines
• Medical devices
• Other links & information

• Copyright, security, disclaimer, privacy

Presentations from the July ANZTPA stakeholder information sessions on the proposed regulation of homoeopathic medicines, anthroposophic medicines and essences

July 2006

On 11 and 13 July, 2006, Medsafe and TGA jointly sponsored information sessions on the proposed approach to the regulation of homoeopathic and anthroposophic medicines, and essences, in the Australia New Zealand Therapeutic Products Authority (ANZTPA).

The aim of these information sessions was to:

• Clarify the proposed approach to the regulation of homoeopathic and anthroposophic medicines, and essences, which was developed on the basis of stakeholder comment.
• Outline strategies that are being considered to address such matters as practitioner availability and validity of product.
• Work with stakeholders to identify any outstanding issues and unintended consequences of the proposed system.

One Information Session was held in Auckland, New Zealand (Tuesday 11 July), and one was held in Sydney, Australia (Thursday 13 July).

The sessions were attended by a range of stakeholders, including manufacturers and sponsors, practitioners, consumer groups and educators. These meetings provided an opportunity for individuals and groups to gain a more comprehensive understanding, not only of the proposed approach to the regulation of these products, but also of the positions held by other stakeholders.

The first part of the information session provided an overview of the proposed regulatory scheme and processes. This was followed by a summary of the outcomes of the consultation on homoeopathic and related medicines (released for public comment in January 2005), and an outline of the provisions relating to the proposed regulation of homoeopathic, anthroposophic and essence products which have been included in the Draft Medicines Rule.

Attendees were given the opportunity to discuss issues of quality standards, including GMP; permitted ingredients for these categories of products; evidentiary requirements to support indications and claims, and raise any other matters of concern.

A copy of the consolidated presentations made at the meetings can be downloaded below.

Presentations from the July ANZTPA stakeholder information sessions on the proposed regulation of homoeopathic medicines, anthroposophic medicines and essences (pdf,223kb)

URL: http://www.anztpa.org/cm/0607pres-is-hae.htm
PDF: http://www.anztpa.org/cm/0607pres-is-hae.pdf

Top of page